



COVID-19 Resources: Guidance for Chan Researchers

Featured news and announcements

COVID FAQs and new funding opportunities for the period 04/02/21– 04/09/21

As COVID-19 spreads across the globe, new research funding opportunities are cropping up, along with questions regarding how COVID-19-related disruptions to research might affect current federal funding. Answers to many of those questions and information on a variety of new funding opportunities is provided by clicking on the related link below:

1. [Covid-19 research funding opportunities](#)
2. [COVID-19 related research news and policy updates](#)
3. [Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19](#)
4. [Free access and free services for researchers related to COVID-19](#)
5. [COVID-19 news by Chan faculty](#)

1. [COVID-19 research funding opportunities](#)

Internal COVID-19 Funding Announcements

Non-federal COVID-19 Funding Announcements

NOTE: When applying for external awards, PIs and grant managers should closely review the terms and conditions for potential conflicts. Any questions should be referred to Harvard Chan School SPA. In addition, ALL sponsored proposals must be reviewed by SPA 7 days before the sponsor due date, so please allow appropriate lead time to work with your grant manager prior to the SPA deadline. Additional information on SPA proposal development policies can be found [here](#).

[COVID-19 Early Treatment Fund \(CETF\): Outpatient Trials for Repurposed Drugs](#)

Deadline: None specified

The CETF focuses on funding outpatient clinical trials to repurpose existing drugs for effective COVID-19 treatment. The goal is to rapidly test and implement the use of drugs that have already gone through extensive safety testing and are currently approved and marketed for other indications, as these will be much faster to mass-produce than new drugs. The CETF is funding an array of well-designed outpatient clinical trials in parallel to quickly identify which existing drugs work to treat COVID-19. All funded trials go through a rigorous review process by the organization's Scientific Advisory Board before being approved. The CETF is interested in trial designs that incorporate next-generation DNA sequencing to identify virus variants and human variants that lead to better or worse outcomes in order to triage patients.

[PCORI: Engagement Award Special Cycle: Building Capacity for PCOR/CER for Topics Related to COVID-19](#)

Deadline: May 24, 2021

This award aims to support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER process on topics that address health

outcomes related to COVID-19. Projects will also provide an understanding of the impact of stakeholder engagement strategies within different settings and stakeholder groups focused on this special area of interest.

***NEW: PCORI: Engagement Awards Special Cycles Launch for Projects on COVID-19, IDD**

Deadline: May 24, 2021

This PFA supports projects that enable organizations and communities to build capacity and skills to participate across all phases of PCOR/CER. Projects should explore and address the urgent and unique needs specifically related to: the long-term effects of post-acute COVID-19; the impact of COVID-19 on disproportionate affected populations; the impact of COVID-19 on social isolation and loneliness (mental health and well-being); engaging, educating, and promoting informed decision making around COVID-19 vaccines. Other relevant topics related to COVID-19 health outcomes with appropriate justification will also be considered. View the PFA for more details and to apply.

International Research Development Centre: Women's Economic Empowerment in a Low-Carbon COVID-19 Recovery

Deadline: April 13, 2021

The Women's Economic Empowerment in a Low-Carbon COVID-19 Recovery call for proposals supports projects that will support the generation and use of nationally and locally relevant evidence on women's economic empowerment in a low-carbon COVID-19 recovery in the Global South. Projects should support the generation of solutions-oriented, local research and evidence that helps address the specific and systemic barriers women face during and after the COVID-19 pandemic and in accessing opportunities that arise in new low-carbon economic activities. Projects should address new barriers that have arisen during the pandemic, the continued disproportionate burden of unpaid care work and gendered social norms, and ways to support and scale women-led initiatives that promote sustainable recovery.

Stop the Spread

Deadline: None

Stop the Spread seeks to address the critical needs of the COVID-19 pandemic in four key ways: research, partnerships, investments, and hyperlocal support. Investments are provided in the form of grant or equity capital to nonprofit and for-profit organizations with novel solutions providers that uniquely address the needs of underserved communities. Organizations interested in exploring collaborations with Stop the Spread may contact them using the [online form](#).

Global Innovation Fund: COVID-19 Response

Deadline: Rolling

The Global Innovation Fund is a non-profit innovation fund that invests in the development, rigorous testing, and scaling of innovations targeted at improving the lives of the world's poorest people, i.e., those living on less than \$5 a day. For-profit companies located anywhere in the world can apply for funding for projects that address COVID-19 in developing countries. GIF supports innovators at all stages of their life cycle, from start-up and pilot-testing through to larger-scale implementation.

Robert Wood Johnson Foundation: Systems for Action: Supplemental Research on COVID-19 Response and Recovery

Deadline: July 20, 2021

The need to identify successful system alignment strategies has become increasingly urgent in the wake of the SARS-CoV-2 virus pandemic that causes COVID-19. This pandemic places people with unmet health and social needs at heightened risk of infection and complications, while propagating unmet needs

through job losses, school and business closures, occupational risks, and social distancing policies. This call for proposals (CFP) will provide supplemental research funding to teams that are already engaged in the study of a promising system alignment mechanism, with the objective of learning how this mechanism performs in addressing health and social needs during the COVID-19 pandemic.

[The PhRMA Foundation: Valuing Health Equity Challenge Award](#)

Deadline: December 1, 2021

This Challenge Award aims to inspire bold and vital research on how value assessment can better capture evidence regarding diverse populations and drivers of health disparities.

[Pfizer: COVID 19 General Research Grants](#)

Deadline: Not indicated

Pfizer is currently accepting COVID-19 general research grant requests that address the following areas:

- Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations
- Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer's vaccine particularly in specific patient populations
- Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake

[King Badouin Foundation: Sofina COVID Solidarity Fund](#)

Deadline: None

The Sofina COVID Solidarity Fund wishes to address the adverse consequences of the global COVID-19 pandemic on two key issues related to Sofina's focus sectors: specific challenges in healthcare systems and services and the digital gap in education. The Fund will be active for two years and will fund projects which have clearly identified the root causes of a problem in one of the above fields and found a creative and innovative way to solve them in the long term. Selected projects will receive a minimum amount of €500,000. Nonprofit organizations setting up a project in Western Europe, India, or Singapore are eligible to apply.

[The Boehringer Ingelheim: IIS Program](#)

Deadline: continuous

This program is offered to all qualified academic and community-based scientists or consortia who are interested in independently proposing and conducting their own research to evaluate potential clinical and non-clinical investigations involving COVID-19 related matters including safety, clinical outcomes, antiviral effects, or antithrombotic benefits.

[The American Lung Association: COVID-19 and Emerging Respiratory Viruses Research Award](#)

Deadline: May 30, 2021

This award invites applications for its COVID-19 and emerging respiratory viruses research award. This supports research focusing on emerging respiratory pathogens like SARS-CoV-2. Projects must directly be related to COVID-19 or other viral respiratory threats that may arise in the future.

[Innovation for Poverty Action: Peace & Recovery Program: COVID-19 response](#)

Deadline: Rolling

For time-sensitive research or additions to research projects that study or support the COVID-19 response. This funding window could support projects that:

- Generate new data to directly inform the COVID-19 response of committed partners

- Evaluate interventions that are expected to improve COVID-19 response or recovery
- Add a module to an existing survey in order to track COVID-19 exposure or response
- Add a treatment arm that may support communities' resiliency in response to COVID-19
- Anonymize, curate, and share already-collected data quickly so that it can be used for decision-making by the humanitarian community
- Conduct a "downstream survey" that follows up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities' response to COVID-19

Successful applicants will have a research team or staff that has the necessary experience to study the emergency response. As a result, interdisciplinary teams are encouraged.

[Mercatus Center: COVID-19 Response: A Call for Ideas](#)

Deadline: Rolling

The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic, specifically, in the topics of restarting and reopening, institutional challenges, health and science policy, economic and regulatory policy, and monetary policy.

[Biogen Foundation: COVID-19 Relief Effort](#)

Deadline: Unspecified (accepting applications)

The Biogen Foundation has committed \$10M to aid in COVID-19 relief efforts around the world. At this time, the Biogen Foundation's COVID-19 relief efforts are focused on the following categories: Expanding and ensuring access to testing; Easing the burden on healthcare systems and healthcare workers; Providing food and necessities for our most vulnerable populations.

[Draper Richards Kaplan: Coronavirus Urgent Response Initiative](#)

Deadline: Not specified

This initiative supports ideas that are tackling the most acute and time-critical social problems caused by the Covid-19 pandemic right now. DRK wants to help jumpstart projects that can realistically deploy within 30 days.

[Robert Wood Johnson: Pioneering Ideas: Exploring the Future to Build a Culture of Health](#)

Deadline: Continuous

This award seeks ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. While this call for proposals is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, we recognize the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

[Amgen Foundation: COVID-19 Relief Support](#)

Deadline: none

The Amgen Foundation is dedicated to combating this pandemic by working across several fronts to apply their unique strengths in genetics, immunology, and antibody engineering to prevent and treat COVID-19. The Foundation's COVID-19 Relief Support program is dedicated to supporting patients and communities in the fight against COVID-19. Support is provided in the U.S., including Puerto Rico.

[Merck KGaA: Research Grant for Pandemic Preparedness](#)

Deadline: Rolling

This grant seeks proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.

[Patient-Centered Outcomes Research Institute: Enhancements to existing Research Projects and Engagement Awards](#)

Deadline: Rolling

PCORI is requesting enhancements to existing Research Projects and Engagement Awards that can be initiated quickly to influence the outcome of the current pandemic and that have some relationship to the original award, using existing teams that are currently funded: [COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects](#); [COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards who has funding](#)

[Fast Grants: Fast Funding for COVID-19 Science](#)

Deadline: Not announced

These grants are for scientists at an academic institution currently working on a COVID-19 related project and in need of funding. Fast Grants are \$10k to \$500k and decisions are made in under 48 hours.

[Mozilla: COVID-19 Solutions Fund](#)

Deadline: Rolling

The fund will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related

[California Institute for Regenerative Medicine \(CIRM\)](#)

Deadline: Open on a bi-monthly basis.

The CIRM has allocated \$5 million in funding for peer-reviewed regenerative medicine and stem cell research that could quickly advance treatments for COVID-19. Support is provided for promising discovery, preclinical, and clinical trial stage projects.

[Nellie Mae Education Foundation: Racism is a Virus Too](#)

Deadline: Rolling basis until resources are exhausted

The Nellie Mae Education Foundation created a rapid response fund to respond to the hate crimes and bias against Asian American communities in New England resulting from COVID-19.

[Omidyar Network India: Rapid Response Funding for COVID-19](#)

Deadline: Not announced

The Omidyar Network India has announced a rapid response window to fund proposals that support the lower 60% of India's income distribution in managing and mitigating the challenges that come with Covid-19. Support is provided for initiatives that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19.

[Open Road Alliance](#)

Deadline: Not announced

The Open Road Alliance is offering charitable grants to organizations responding directly to COVID-19,

with priority given to organizations and activities that have a clear and direct role in ‘flattening the curve’ and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Loans are also available to organizations affected by COVID-19, including those with lost event revenue, those delivering vital community services, and social enterprises.

[Bill & Melinda Gates Foundation, Wellcome and Mastercard: COVID-19 Therapeutics Accelerator](#)

Deadline: varies

This initiative speeds development and access to therapies for COVID-19 by coordinate R&D efforts and removing barriers to drug development and scale-up to address the epidemic. Gokhan

2. Federal COVID-19 Funding Announcements

National Institutes of Health:

[Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center \(U24 Clinical Trial Not Allowed\)](#)

Deadline: 06-09-2021

[*NEW: NIH: Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium \(U01 Clinical Trial Not Allowed\)](#)

Deadline: 06-09-2021

[NIH: SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R03 Clinical Trial Not Allowed\)](#)

Deadline: Apr 15, 2021

[NIH: SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R01 Clinical Trial Not Allowed\)](#)

Deadline: Apr 15, 2021

[NIH: SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R21 Clinical Trial Not Allowed\)](#)

Deadline: Apr 15, 2021

[NIH: Immune Development in Early Life \(IDEaL\) \(U19 Clinical Trial Not Allowed\):](#)

Deadline: June 5, 2021

This announcement support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens, and environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.

[NIH: Immune Development in Early Life \(IDEaL\) \(U01 Clinical Trial Not Allowed\)](#)

Deadline: June 5, 2021

The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens or environmental pollutants on immune ontogeny and

function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.

[NIH: Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\) and Coronavirus Disease 2019 \(COVID-19\) \(R01 Clinical Trial Not Allowed\) \(PAR-20-178\)](#)

Deadline: Rolling, 9/14/2020 through 09/14/2021

This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

[NIH: Rapid Acceleration of Diagnostics \(RADx\) Initiative for COVID-19](#)

Deadline: rolling

NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution. Project proposals accepted through online [RADx portal](#).

NIH Notices of Special Interest:

[*NEW: Notice of Special Interest \(NOSI\): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children](#)

Deadline: Various through 9/2022

[NIH: Notice of Special Interest \(NOSI\): Administrative Supplements to FIC Awards for COVID-19-related Research in Low- or Middle-Income Countries](#)

Deadline: May 15, 2021

[NIH: Notice of Special Interest \(NOSI\): Administrative Supplements for COVID-19-Impacted FIC Research Training and Education Awards](#)

Deadline: May 15, 2021

[NIH: Notice of Special Interest \(NOSI\): Telehealth Strategies for Individuals with HIV and Substance Use Disorders](#)

Deadline: Sep 8, 2024

[NIH: Notice of Special Interest \(NOSI\): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19](#)

Deadline: Sep 8, 2024

[NIH: Notice of Special Interest \(NOSI\): Complement in Basic Immunology \(CIBI\)](#)

Deadline: Jan 8, 2023

NIH: Notice of Special Interest: Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations

Expiration date: May 6, 2021

NIH: Notice of Special Interest: Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations

Expiration date: May 6, 2021

NIH: Notice of Special Interest (NOSI): Administrative Supplements to SEPA Awards to Develop Innovative Educational Resources to Address SARS-CoV-2 Vaccine Hesitancy

Expiration date: May 1, 2021

NIH: Notice of Special Interest (NOSI): Administrative Supplements to SEPA Awards to Develop Innovative Educational Resources to Address SARS-CoV-2 Vaccine Hesitancy

Expiration date: May 1, 2021

NIH: Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for NIH Grants to Add or Expand Research Focused on Maternal Health, Structural Racism and Discrimination, and COVID-19

Expiration date: Apr 14, 2021

NIH: Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs to Address SARS-CoV-2 Vaccine Hesitancy

Expiration date: May 1, 2021

NIH: Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs to Address SARS-CoV-2 Vaccine Hesitancy

Expiration date: May 1, 2021

NIH: Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs

Expiration date: Aug 17, 2024

NIH: Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration

Expiration date: May 8, 2023

NIH: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Expiration date: Dec 16, 2021

NIH: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Expiration date: Dec 16, 2021

NIH: Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs for SARS-CoV-2 Surveillance Studies

Expiration date: Apr 1, 2021

NIH: Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation

Deadline: May 4, 2021

NIH: Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation

Deadline: Sep 8, 2024

NIH: Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control

Deadline: Apr 1, 2021

NIH: Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs

Deadline: Aug 17, 2024

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trials Not Allowed)

Deadline: Feb 28, 2021

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trials Not Allowed)

Deadline: Feb 28, 2021

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trials Not Allowed)

Deadline: Feb 28, 2021

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trials Not Allowed)

Deadline: Feb 28, 2021

NIH: Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)

Deadline: May 8, 2023

NIH: Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases

Deadline: November 19, 2021

The purpose of this Notice is to announce to potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) an interest in research on the impact of COVID-19 as related to diseases and conditions within the NIAMS mission.

NOSI: [Administrative Supplements for COVID-19 Impacted NIMH Research](#)

Deadline: June 02, 2023

The focus of this NOSI is to inform the research community that the NIMH is supporting administrative supplements (in scope of parent award) to cover unanticipated costs caused by the COVID-19 pandemic or related mitigation efforts that could not be covered by rebudgeting existing funds. Unfortunately, available resources for such supplements are significantly limited in FY2021, and the NIMH acknowledges that we will **not** be able to fund all requests. To stretch these resources, the NIMH asks that non-monetary solutions be considered and exhausted before requesting additional funds and that investigators apply only in cases of significant need. In addition, to distribute the costs of these supplements over the next few years, the NIMH encourages the submission of administrative supplements only in the last year of award, although special consideration may be given in unusual circumstances. Supplement applications for funding consideration during the first year of the parent award (new and competing renewals) will **not** be considered responsive to this NOSI. Finally, it is likely that NIMH will need to prioritize requests and will do so based on the program priorities listed below. Applicants are strongly encouraged to contact the Program Officer of the parent award before submitting a supplement application.

[NIH: Notice of Special Interest \(NOSI\): Availability of Emergency Administrative Supplements to Clinical and Translational Science Award \(CTSA\) Program Awards to Address 2019 Novel Coronavirus Disease \(COVID-19\) Public Health Needs](#)

Deadline: Rolling through June 2, 2021

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through [PA-20-272](#)) from current Clinical and Translational Science Award (CTSA) UL1 component award recipients from these FOAs:

- [PAR-18-940](#) Clinical and Translational Science Award (U54 Clinical Trial Optional)
- [PAR-18-464](#) Clinical and Translational Science Award (U54 Clinical Trial Optional)
- [PAR-15-304](#) Clinical and Translational Science Award (U54 Clinical Trial Optional)
- [RFA-TR-14-009](#) Clinical and Translational Science Award (U54 Clinical Trial Optional)

NCATS expects to issue 2-9 awards (anticipated to be \$30,000 to \$60,000 Direct Costs) for provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data.

[NIH: Emergency Awards: Notice of Special Interest \(NOSI\) on Pan-Coronavirus Vaccine Development Program Projects](#)

Deadline: June 12, 2021

To advance pan-CoV vaccine development, this program will support research to design and develop vaccine approaches intended to provide durable immunity against CoVs with an emphasis on CoVs with pandemic potential.

[Notice of Special Interest \(NOSI\): Effects of smoking and vaping on the risk and outcome of COVID-19 infection](#)

Deadline: September 8, 2024

The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.

[NIH: NOSI: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract](#)

Deadline: July 16, 2023

Invites applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. Investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific. Apply via [PA-20-185](#) or [PA-18-482](#).

[NIH: NOSI: The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury \(ARDS/ALI\)](#)

Deadline: July 6, 2024

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).

[NIH: Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 \(COVID-19\) \(NOT-MH-20-061\)](#)

Deadline: TBA

NIMH has already made a significant investment in a [data repository](#) to hold human subjects data related to mental illness and related fields. This repository allows data from multiple sources to be aggregated and easily accessed by the research community. However, the data repository is most useful when research laboratories collect data using the same set of data elements. With this Notice, NIMH offers guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes that were previously discussed in [NOT-MH-15-009](#) and a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2 virus (the virus that causes COVID-19). The goal of this Notice is to reduce proliferation of one-off survey items and to facilitate data integration, collaboration, and comparisons across data sets.

[NIH: Notice of Special Interest \(NOSI\): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\) & Coronavirus Disease 2019 \(COVID-19\) \(NOT-AT-20-012\)](#)

Deadline: Rolling

To rapidly establish scientific evidence and/or elucidate the mechanism of action of natural product-based remedies for SARS-CoV-2 and COVID-19, NCCIH is encouraging the submission of applications for administrative supplements or competitive revisions of active NCCIH grants.

[NIH: Notice of Change to Eligible Activity Codes for NOT-NS-20-051 "Notice of Special Interest: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System" \(NOT-NS-20-074\)](#)

Deadline: April 15, 2021

The purpose of this notice is to inform interested applicants of a change to the eligible activity codes for [NOT-NS-20-051](#) "Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System". Effective immediately, the RF1 activity code will be added as an eligible activity code to [NOT-NS-20-051](#), for applications submitted to both, [PA-18-591](#) "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) " and [PA-18-935](#) "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)".

[NIH: Notice of Special Interest \(NOSI\): Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System \(NOT-NS-20-051\)](#)

Deadline: May 1, 2020-April 15, 2021

NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS's scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

[Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis \(NOT-CA-20-054\)](#)

Deadline: Not announced

The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients' disease progression, response to therapy, care delivery, or survivorship.

[NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System](#)

Deadline: April 14, 2021

This NOSI highlights the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS's scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

[Notice of Special Interest \(NOSI\): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 \(COVID-19\)](#)

Deadline: May 1, 2021

NIA is encouraging the submission of applications for either Administrative Supplements ([PA-18-591](#)) or Competitive Revisions ([PA-18-935](#)) to active grants to address the following research areas of interest: [Division of Aging Biology](#) (DAB) Research Interests; [Division of Neuroscience](#) (DN) Research Interests; [Division of Geriatrics and Clinical Gerontology](#) (DGCG) Research Interests; [Division of Behavioral and Social Research](#) (DBSR) Research Interests.

[Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 \(COVID-19\) within the Mission of NIAAA](#)

Deadline: through April 16, 2021

This NOSI encourages applications to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

[Notice of Special Interest \(NOSI\) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus \(NOT-TR-20-017\)](#)

Deadline: Rolling - May 15, 2020- January 26, 2022

For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

[Notice of Special Interest \(NOSI\) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus \(NOT-TR-20-016\)](#)

Deadline: Rolling - May 15, 2020 through January 25, 2022

For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

[Notice of Special Interest \(NOSI\) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus \(NOT-MH-20-047\)](#)

Deadline: Rolling - March 27, 2020-April 16, 2021

For research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

[Notice of Special Interest \(NOSI\): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 \(COVID-19\) \(NOT-ES-20-015\)](#)

Deadline: Rolling - May 01, 2020-May 04, 2021

For research to understand the impact of environmental exposures on (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus. NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

[Notice of Special Interest \(NOSI\) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus \(NOT-DA-20-047\)](#)

Deadline: March 31, 2021

NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: [PA-18-935](#) Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional); and [PA-18-591](#) Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

[NIH: Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus](#)

Deadline: Applications will be accepted on a rolling basis through March 31, 2021

NIDA is issuing this notice to highlight the urgent need for research on the 2019 Novel Coronavirus. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Other federal agencies:

[CDC: National Initiative to Address COVID-19 Health Disparities](#)

Deadline: May 03, 2021

The program titled “National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved, Including Racial and Ethnic Minority Populations and Rural Communities” will provide funding to state, local, U.S. territorial and freely associated state health departments (or their bona fide agents) to address COVID-19-related health disparities and advance health equity by expanding state, local, U.S. territorial and freely associated state health departments capacity and services to prevent and control COVID-19 infection (or transmission).

[Biomedical Advanced Research and Development Authority \(BARDA\)](#)

Deadline: October 31, 2021

Proposals for diagnostic assay development are solicited under Area of Interest (AOI) 7.7; projects to develop COVID-19 therapeutics, including direct-acting antivirals and host-directed therapeutics, may be submitted under AOI 9.2; and projects to develop and demonstrate innovations and enhancements to pharmaceutical manufacturing platforms to support the development of vaccines and therapeutics for COVID-19 can be submitted under AOI 17

[Biomedical Advanced Research and Development Authority: Mask Innovation Challenge: Building Tomorrow’s Mask](#)

Deadline: April 21, 2021

BARDA’s Division of Research, Innovation, and Ventures (DRIVE), in partnership with the National Institute for Occupational Safety and Health (NIOSH), has issued a challenge to support the development of innovative masks that can protect against respiratory pathogens such as SARS-CoV-2. The Mask Innovation Challenge has two phases: Ideation and Prototyping. In Phase 1, respondents will be asked to submit their concepts for a redesigned mask according to the published criteria. Up to 40 regional winners (within up to 4 regions) will be selected to move on to the DRIVE Accelerator Shark Tank Pitch Competition, where they will present their design to a panel of experts. Of those finalists, up to 10 will be selected to receive a prize of up to \$10,000 each to create a prototype of their concept. Prototypes and physical products will not be tested in Phase 1. In Phase 2, finalists will be invited to submit a lot of prototypes for proof-of-concept testing by NIOSH laboratories, and 5 winners will be selected.

[Centers for Disease Control: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region](#)

Deadline: April 20, 2021

The program titled Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (EMR) aims to strengthen capacity and performance of national immunization programs in countries of the EMR to achieve regional vaccine preventable disease (VPD) control, elimination, and eradication targets (i.e., polio eradication, measles and rubella elimination), reduce VPD-related morbidity and mortality, and address emerging public health threats such as coronavirus disease 2019 (COVID-19).

[EPA: Environmental Justice Small Grants \(EJSG\) Program](#)

Deadline: May 7, 2021

The EPA is working to improve the environment and public health conditions of low-income communities and communities of color through the advancement of racial equity and environmental justice. This announcement places emphasis on projects focusing on COVID-19 impacts, as well as climate and disaster resiliency.

[U.S. Department of State: 2020 TIP Office Annual Program Statement to Address Impacts of COVID-19](#)

Deadline: June 30, 2021

The Department of State's Office to Monitor and Combat Trafficking in Persons (TIP Office) has announced an open competition for funding to address the impacts of COVID-19 on efforts to combat human trafficking and support government measures to counter human trafficking. Applicants may submit applications for no less than \$100,000 to work in one or more countries. Organizations eligible to apply include U.S.-based and foreign non-profits, non-governmental organizations (including faith-based organizations), for-profit organizations, institutions of higher education, and public international organizations.

[HHS: Community Health Workers for COVID Response and Resilient Communities \(CCR\) Evaluation and Technical Assistance \(ETA\); CCR-ETA Forecast 1](#)

Deadline: May 22, 2021

This three-year opportunity provides funds to conduct a national evaluation of the Community Health Workers for COVID Response and Resilient Communities (CCR) program, DP21-2110 and provide training and technical assistance (TA) to CCR recipients. This program has two components: A) conduct a national evaluation of the CCR and B) deliver training and TA to CCR recipients. Applicants may only apply for 1 component.

[CDC: Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services to Mitigate Morbidity and Mortality](#)

The overall goals of this operational research are to a) improve mortality and cause of death estimation during the acute emergency phase, b) understand COVID-19 disease transmission, contributing factors and secondary health consequences, c) study the effects of various hand hygiene interventions on mitigating the spread of COVID-19 and d) understand the mental health impact of COVID-19 to reduce associated morbidity and mortality among displaced populations and in emergency settings.

[DHHS Administration for Community Living/: Aging and Disability Resource Center/No Wrong Door System Funding Opportunity: Critical Relief Funds for COVID-19 Pandemic Response](#)

Deadline: None specified

The purpose of this emergency FOA is to support capacity and resource allocation at the state, local and territorial level to ensure coordination across agencies and support immediate response to urgent needs resulting from COVID-19. Funding will enable states and territories to support ADRCs in providing critical access functions to those populations most at risk of COVID-19 and mitigate adverse effects resulting from this national pandemic such as social isolation, limited access to nutritional supports and personal care services, etc. Additionally, funds would enable ADRCs to enhance and increase virtual access to services such as utilizing telehealth technologies to engage with health care practitioners and case managers.

[HHS: Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\) and Coronavirus Disease 2019 \(COVID-19\) \(R21 Clinical Trial Not Allowed\) \(PAR-20-177\)](#)

Deadline: April 30, 2021

This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

[NSF: Dear Colleague Letter 20-052 re Corona Virus Proposals](#)

Deadline: varies

NSF is accepting proposals to model, track, inform, educate, and prevent the spread of Coronavirus through its [existing funding opportunities](#). NSF invites researchers to use the [Rapid Response Research \(RAPID\) funding mechanism](#), which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Visit [NSF, Dear Colleague 20-053](#) for Coronavirus proposal FAQs and conditions and process for proposal deadline extension.

[NSF-Office of Advanced Cyberinfrastructure \(OAC\), Dear Colleague Letter 20-055](#)

Deadline: varies

OAC is inviting [Rapid Response Research \(RAPID\) funding mechanism](#) proposals and supplemental funding requests to [existing awards](#) that address COVID-19 challenges through data and/or software infrastructure development activities.

[DOE: Invitation for COVID-19 Scientific Questions \(DOE Resources\)](#)

Deadline: Ongoing

The Department encourages scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. Please send research questions that the scientific community may address with DOE resources by email to SC.DCL@science.doe.gov.

[USAID/Bangladesh and the Private Sector: Partnering to Fight COVID-19 Agency for International Development](#)

Deadline: April 29, 2021

The goal of the USAID Bangladesh and the Private Sector: Partnering to Fight COVID-19 program is to provide a medium through which organizations can work with USAID and the private sector to build Global Development Alliances (GDAs) that will: a) respond to the current outbreak of COVID-19 in Bangladesh; b) address important business interests and objectives; and c) advance USAID's strategic priorities and objectives.

Previously Announced NIH Limited Submission Opportunities

3. COVID-19 related research news and policy updates

A few of the provisions in the third COVID-19 relief/response package that might be of particular interest to researchers is below. To read more, please download a [section-by-section summary](#) and the [legislative text](#).

- ESI status can be extended due to disruptions From COVID-19. Click [here](#) for instructions.
- NIST - \$6 million to provide continuity of operations and to conduct research and measurement science to support the testing and treatment of coronavirus. Page 622 of the legislative text.
- NSF - \$75 million to support research at molecular, cellular, physiological and ecological levels to better understand coronavirus genetics, modes of action, transmission, virulence, and population dynamics. It is expected that many of these funds will be available through the Rapid Response Research funding mechanism. [Read Dear Colleague Letter here](#). Page 629.

- DOE Office of Science - \$99.5 million for costs related to equipment, personnel, and operations to support research on the coronavirus, including support to provide access to user facilities. Page 654.
- EPA S&T - \$1.5 million to support research efforts regarding coronavirus – and specifically, research on methods to reduce risks from environmental transmission via contaminated surfaces. Page 713.
- CDC - \$4.3 billion to support federal, state, and local public health agencies to prevent, prepare for and respond to the coronavirus. Included in that amount is \$500 million for global disease detection and emergency response, \$500 million for public health data surveillance and analytics infrastructure modernization, and \$300 million for the Infectious Diseases Rapid Response Reserve Fund, which supports immediate response activities during outbreaks. Page 728.
- NIH - The bill includes \$945 million to support research and expand on prior research plans, including developing an improved understanding of the prevalence of COVID-19, its transmission and the natural history of infection, and novel approaches to diagnosing the disease and past infection, and developing countermeasures for the prevention and treatment of its various stages. Of this total, \$103 million is allocated for NHLBI, \$706 million NIAID, \$60 million NIBIB, \$36 million NCATS, \$30 million OD, and \$10 million for National Library of Medicine. When combined with the first supplemental, Congress has provided \$1.78 billion for NIH research on COVID 19. Page 730.
- BARDA (Biomedical Advanced Research and Development Authority) - At least \$3.5 billion to advance construction, manufacturing, and purchase of vaccines and therapeutics to the American people.
- NASA - \$60 million to support NASA with resources for operational adjustments associated with mission delays caused by NASA center closures related to coronavirus. Page 628. Also, the package includes a number of health-related authorizations, including the HRSA health professionals and nursing workforce development programs.

4. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19

NIH

- [Chart](#) showing the various flexibilities provided for the current and next round of peer review.
- [Considerations for New and Ongoing Human Subjects Research During the COVID-19 Public Health Emergency](#) under Human Subjects
- [Coronavirus Update: Guidance for Peer Reviewers](#)
- [OHRP Guidance on COVID-19](#) under Human Subjects and Clinical Trials
- [NHLBI Announces Availability of Frequently Asked Questions \(FAQs\) for NOT-HL-20-757, Notice of Special Interest \(NOSI\): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 \(COVID-19\) \(NOT-HL-20-759\)](#)
- [notice on Guidance for Cost-Related Flexibilities Available to Support of Competitive Research \(SCORE\) Award Recipients Affected by COVID-19](#)
- [Virtual NIH Activities for Trainees Outside the NIH](#)
- [Animal Welfare: COVID-19 Pandemic Contingency Planning for Animal Care and Use Programs](#)
- [Coronavirus Disease 2019 \(COVID-19\): Information for NIH Applicants and Recipients of NIH Funding](#). The page now includes a link to [page update history](#) so you can easily see what's new.
- [New guidance of flexibilities for awardee, students and conference funding during COVID-19 period](#)
- [FAQs](#) including new section on Training, Fellowship and Career Development Awards
- [An FAQ to address questions regarding proposal submission and award management](#)
- [A lenient late-application policy](#) for those who are unable to meet application deadlines due to the COVID-19 emergency

- NIH grant recipients may [extend the final budget period](#) of the approved project on active grants one time for up to 12 months without requesting prior approval from NIH

Other Federal Guidance

- [USAMRAA's Supplemental Guidance on Administrative Flexibilities for Grants and Cooperative Agreements in Response to COVID-19 Pandemic](#)
On March 19, 2020 OMB issued Memorandum M-20-17 Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19) due to Loss of Operations.
- [Frequently Asked Questions \(FAQs\)](#) published by The Department of Defense (DoD)

5. Free access and free services for researchers related to COVID-19

- [NIH VideoCast](#) is a free National Library of Medicine webinar for researchers to learn how to share, discover, and cite COVID-19 data and code in generalist repositories.
- [NIH Resource to Analyze \(COVID-19\) Literature: The COVID Portfolio Tool](#)
[NIH Office of Portfolio Analysis](#) (OPA) has built a comprehensive listing of (COVID-19) publications, available to the public. The portfolio is updated daily and draws from [PubMed](#) resources for citations and abstracts of published biomedical literature.
- [The COVID-19 High Performance Computing \(HPC\) Consortium](#) is a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy and IBM to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines.
- [COVID-19 Collaboration Platform](#): This platform is a home for RCT protocols that are available for collaboration.
- [CD2H COVID Case Report Forms and Phenotyping Standards website](#)
- [The Center for Leading Innovation and Collaboration COVID-19 page](#)
- The American Heart Association is working to ensure optimal care for patients with cardiovascular disease who contract coronavirus (COVID-19). Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with COVID-19. Here are [helpful resources](#) for health systems, clinics, care providers, patients and the public.
- [National Library of Medicine](#), through its GenBank® sequence database, is providing the biomedical community free and easy access to [genome sequences from the novel coronavirus](#) associated with the recent outbreak of pneumonia in Wuhan, China. The outbreak was declared a global health emergency on January 30, 2020 and GenBank® continues to rapidly release data associated with this outbreak as it comes in and welcomes sequence data [submissions](#) as well.
- Internal: [FAS Research Computing](#) has offered to provide enhanced support to Harvard Chan School research related to COVID-19. Examples of support include help with workflow automation to improve efficiency for COVID-19 data analysis, and prioritized assistance for virtual machine requests for hosting a COVID-19 analytic tools website. For more information, please contact the FASRC team via [email](#) or attend one of their [virtual office hours](#) which are held weekly on Wednesdays from 12 PM to 3 PM.
- [Open Research Dataset](#) (CORD-19) is a resource of over 45,000 scholarly articles, including over 33,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses.
- [IBM has resources to share](#) — like supercomputing power, virus tracking and an AI assistant to answer citizens' questions.

- [LitCovid](#) is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus.
- The National Institute of Allergy and Infectious Diseases (NIAID) has made 2019 SARS-CoV-2 and other Coronavirus strains and reagents available through its [BEI Resources Repository](#).
- [The American Journal Experts](#) are offering free language editing and translation services for articles related to coronavirus disease 2019
- [Sharing research data and findings relevant to the novel coronavirus \(COVID-19\) outbreak](#), with NIH as a signatory to the statement Wellcome Trust news, January 31, 2020
- The BMJ: [Coronavirus](#)
- [Chongqing VIP Information](#), a Chinese journal database
- Elsevier: [Novel coronavirus information center](#)
- *The Lancet*: [COVID-19 resource centre](#)
- *New England Journal of Medicine*: [free Journal content on coronavirus](#)
- Royal Society of Tropical Medicine and Hygiene: [Coronavirus free collection](#)
- Springer Nature, the publisher of *Nature*: [Novel coronavirus \(SARS-CoV-2 and COVID-19\)](#)
- Wiley Online Library: [COVID-19 resources and news](#)
- WHO: [COVID-19 Course Series](#) - free online courses from OpenWHO

6. COVID-19 news by Chan faculty

- Check out the School's [updated Coronavirus website](#), which showcases our researchers' work on the front lines of the global response to COVID-19:
- Find the latest COVID news by Chan faculty [here](#).